Friday, 16 October 2026European Markets

FINATIS Stock Went Down By Over 27% In The Last 21 Sessions

Loading stream...

finatis (fnts.pa), a french food distribution company, experienced an alarming decline during recent trading sessions. over just 21 days, its stock price declined 27.36% from eur4.02 to eur2.92, falling after five consecutive sessions of losses; even as cac 40 index posted an incremental gain of 0.13 percentage points.

about finatis

finatis is a subsidiary of euris sas that operates food markets and sports equipment stores in france and latin america. however, its unimpressive earnings per share (eps) over the last twelve months (negative eur24.26) may have investors questioning its financial viability.

trading volume and investor activity

notably, the stock's last reported trading volume was 752, almost twice its average trading volume of 113. this may reflect increased investor activity or interest during times of extreme price fluctuation.

earnings per share and investor sentiments

reviewing these developments requires financial literacy surrounding eps (earnings per share). this figure represents the proportion of profit allocated per outstanding share of common stock; therefore a negative eps like finatis may be seen as a warning sign and coupled with their stock price decline may signal investor disillusionment with its health.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com